Company intelligence / Profile preview
Chongqing Paijin Biotechnology
Chongqing, Chongqing Shi, Chinapegbiocq.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chongqing Paijin Biotechnology develops recombinant polypeptides, enzymes, and biosimilars for endocrine/metabolic disorders, immune system diseases, neoplasms, hemic/lymphatic conditions. Its pipeline includes at least two preclinical programs, five in Phase 1/IND approval stage, two in Phase 2 clinical trials or IND approval stage, three in Phase 3 clinical trials or IND approval stage. Notable assets include a pegylated recombinant asparaginase for leukemia/lymphoma in Phase 1 trials and a teduglutide biosimilar for short bowel syndrome in Phase 3.
- Therapeutic areas
- HematologyImmunologyEndocrinologyOncology
- Modalities
- Recombinant polypeptideEnzymeBiosimilar
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
Beyond the preview
Go deeper on Chongqing Paijin Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Paijin Biotechnology.